---
layout: post
title: "Expansion Cohorts: Use in First-in-Human Clinical Trials To Expedite Development of Oncology Drugs and Biologics; Guidance for Industry; Availability"
date: 2026-02-05 18:58:18 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-04397
original_published: 2022-03-02 00:00:00 +0000
significance: 8.00
---

# Expansion Cohorts: Use in First-in-Human Clinical Trials To Expedite Development of Oncology Drugs and Biologics; Guidance for Industry; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** March 02, 2022 00:00 UTC
**Document Number:** 2022-04397

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics." The purpose of this guidance is to provide advice to sponsors regarding the design and conduct of first- in-human (FIH) clinical trials intended to efficiently expedite the clinical development of oncology drugs, including biological products, through multiple expansion cohort trial designs. This guidance finalizes the draft guidance of the same name issued in August 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/03/02/2022-04397/expansion-cohorts-use-in-first-in-human-clinical-trials-to-expedite-development-of-oncology-drugs)
- API: https://www.federalregister.gov/api/v1/documents/2022-04397

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
